AcquisitionsJun 22, 2026, 07:16 AM
AbbVie to Acquire Apogee Therapeutics for $10.9B
AI Summary
AbbVie Inc. announced a definitive agreement to acquire Apogee Therapeutics, Inc. for approximately $10.9 billion in an all-cash transaction, paying $135.11 per share. This acquisition aims to deepen AbbVie's immunology portfolio by adding clinical-stage candidates for inflammatory and immunological diseases, including Apogee's lead asset, zumilokibart (APG777), for atopic dermatitis. The transaction is expected to close in the third quarter of 2026 and become accretive to AbbVie's adjusted diluted earnings per share beginning in 2032.
Key Highlights
- AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash.
- Total equity value of the transaction is approximately $10.9 billion.
- The acquisition adds a diverse pipeline of assets focused on inflammatory and immunological diseases.
- Apogee's lead asset, zumilokibart (APG777), targets IL-13 for atopic dermatitis.
- The transaction is expected to close in Q3 2026, subject to approvals.
- The acquisition is expected to be accretive to AbbVie's adjusted diluted EPS starting in 2032.
Price Impact
More from ABBV